Abstract
Introduction Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique’s progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of AHD is critical to understanding this important condition.
Methods Data from October to December 2023 were reviewed from the 79 health facilities implementing the AHD diagnosis and treatment package at the national level.
Results Overall, 36% (7.811/21.452) of people living with HIV (PLHIV) newly initiated or reinitiated on treatment had a CD4 test, of which 1.986 were diagnosed with AHD. Most diagnosed cases were in the newly initiated PLHIV (1.814) versus reinitiated (179).
Conclusion Low CD4 testing uptake means that AHD remains a serious challenge in Mozambique’s path towards the elimination of HIV as a public health threat.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used PEPFAR Monitoring, Evaluation, and Reporting program. This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy. See e.g., 45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. 241(d); 5 U.S.C. 552a; 44 U.S.C. 3501 et seq.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available from PEPFAR Monitoring, Evaluation, and Reporting program data.
